Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share of Common Stock (Tables)

6 Months Ended

Jun. 30, 2018

The computation of net loss per share for the three and six months ended June 30, 2018 and 2017 is shown below.

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Basic and diluted net loss per share:
Net loss	$	(1,206,074	)	$	(278,445	)	$	(2,302,870	)	$	(500,536	)
Weighted-average number of common shares-basic and diluted		36,623,697			31,745,242			35,951,894			31,745,242

Basic and diluted net loss per share	$	(0.03	)	$	(0.01	)	$	(0.06	)	$	(0.02	)